MKI67 and renal cell carcinoma: Treatment with hispidulin (20 mg/kg) in combination with sunitinib showed decreased Ki-67 labeling index and decreased microvessel density compared to RCC cells treated with sunitinib alone, confirming hispidulin’s efficacy as an antitumor treatment [57].